<DOC>
	<DOCNO>NCT01231113</DOCNO>
	<brief_summary>Malaria pregnancy pose enormous public health challenge , contribute significant maternal infant death yearly . Adverse outcome include maternal anaemia low birthweight . Down regulation cellular immunity increase pregnant woman 's susceptibility malaria mediate adverse outcome . The World Health Organization recommend treatment artemisinin-combination therapy . Ghana use quinine malaria first trim pregnancy artesunate-amodiaquine ( AS-AQ ) quinine use later trimester . Recent amendment add artesunate-lumefantrine dihydroartemisinin-piperaquine ( DHA-PPQ ) antimalarial use country . A high degree safety efficacy DHA-PPQ document several study . DHA-PPQ , though specify use pregnancy , accessible available follow inclusion national malaria guideline may inadvertently use treat malaria pregnancy . Paucity data DHA-PPQ use pregnancy make pertinent study safety , tolerability efficacy pregnancy . We propose open label , randomize control non-inferiority comparison DHA-PPQ AS-AQ treatment uncomplicated malaria pregnancy second third trimester assess safety , tolerability efficacy DHA-PPQ . Outcomes interest include PCR-corrected cure rate day 28 42 , maternal haemoglobin level day 14 42 , prevalence congenital abnormality pregnancy wastage . Proportions percentages describe 95 % Confidence Intervals compare use chi-square test . Parametric non-parametric test significance apply appropriate determine significance difference outcomes treatment group .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Dihydroartemisinin-Piperaquine Uncomplicated Malaria Pregnancy Ghana</brief_title>
	<detailed_description>Pregnant woman age , gravidity gestational age 16-30 week , live within 15 km study center present antenatal care diagnose uncomplicated malaria screen P.falciparum rapid diagnostic test kit obtain consent . Those test positive blood film microscopy do positive blood film microscopy recruit participate study . Participants randomize receive either dihydroartemisinin-piperaquine estimated total dose 6.75mg/kg dihydroartemisinin 55mg/kg piperaquine 3 day round near half tablet ) artesunate-amodiaquine ( artesunate 4mg/kg amodiaquine 10mg/kg two twelve hourly dos daily 3 day ) give informed consent physical examination . This follow home visit day 1 , 3 , 7 , 14 , 28 42 post-treatment ass occurrence adverse event obtain blood sample microscopy , filter paper blot PCR analysis haematology . The mentioned laboratory investigation also conduct recruitment . Participants follow delivery 6 week post-partum gather data maternal peripheral placental parasitaemia , cord parasitaemia , maternal haemoglobin level , low birth weight , stillbirth , preterm delivery , neonatal jaundice , birth defect infant death .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>RDT positive + microscopy confirm P. falciparum parasitaemia . ii ) Informed consent . iii ) Resident within define 15km radius study center . iv ) No history antimalarial treatment precede two week . v ) Assurance adherence study requirement , followup delivery hospital . vi ) Haemoglobin â‰¥ 7g/dl . ) Confirmed multiple gestation . ii ) Severe malaria disease likely influence pregnancy outcome eg renal/ cardiac disease , diabetes mellitus , know pregnancy induce hypertension , know human immunodeficiency virus infection . iii ) Known allergy study medication . iv ) Antimalarial treatment administer third party followup .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>malaria ,</keyword>
	<keyword>pregnancy ,</keyword>
	<keyword>dihydroartemisinin-piperaquine ,</keyword>
	<keyword>efficacy ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>Ghana</keyword>
</DOC>